If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Amers,
From caseboard - DHSC v Primerdesign
30 Apr 2024 09:30 Pre trial review/application hearing
Mrs Justice Jefford.
Court 25.
It stated in caseboard that the hearing was for 1 day, so 'continue at the High Court' possibly means 10 June,
Primerdesign case must go to court.
That's all the hearing was for - to test whether a court case was necessary.
So
"The court will also hear an application by the DHSC for summary judgment in relation to one aspect of its claim, as part of which the DHSC is seeking judgment." The following is the 'one aspect of the DHSC claim which is the summary judgment':
"Exsig failed at an unacceptable rate due to design and/or manufacturing defects and therefore lacked robustness", Mr Heppinstall told the court.
He said that Exsig tests were analysed in seven NHS laboratories, six of which found a failure rate higher than 10% - including four reporting a failure rate of 25%.
Mr Heppinstall said the tests kits were "unfit for public use" putting the companies in breach of the contract."
+++
If Twigger demolishes this claim, (and NCYT has always been clear their tests were not at fault),
I'm not sure there's much else in the DHSC ammunition locker.
16.06.2022 RNS -
"On 15 June 2022, the Company filed a defence of the claim received on 25 April 2022 and a counterclaim of £81.5m against the DHSC. The value of the counterclaim is broadly in line with the amounts previously announced by the Company in its full year 2020 results, plus related interest."
AFAIK we are seeking £81.5m + interest. not the £69.7 m mentioned in this article.
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, announces that Christina Coughlin, MD, PhD, has been appointed as the new Chief Executive Officer of Avacta, effective 1 May 2024.
Why would she immediately get involved in AS's problems when she isn't the CEO this morning.
I think the placing question had to be asked as otherwise InvestorMeet might be accused of avoiding hard questions by it's users - and rightly so.
The detail about the placing might come out as a result of 'everything is on the table' and the needs of a new CEO to show she is willing to deal with shareholder questions fully and fairly, ala efforts to improve comms.
We'll see.
Source - https://uk.investing.com/charts/live-charts live prices.
sp plateauing since 12:15.
That might be because all are at lunch,¯\_(ツ)_/¯ or they're finished.
Eliot possibly a powerful factor in the demise of AS.
He might be fed up with the ex-CEO acting as a loose cannon, or making a wrong decision too many.
He's worked with CC, they quite possibly had speaks about Avacta's CEO position.
SD 'Quite busy', - time to announce a new CEO if there is to be one.
Rory,
A time I think for explaining some of the business / finance issues surrounding AS leadership in 2024.
AS leaves a legacy that requires explanation.
CC has the platform to paint a broader picture of how the situation can be improved.
CLN reduction a priority for CC (I hope)
Comms improvement
I'm thinking CC has lined up / is lining up replacement board members.
Like new R&D head.
Like new comms team
Why not now the focus is Therapeutics in USA.